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Pathophysiology and Treatment of Calcineurin Inhibitor Nephrotoxicity 
Jonna Kemper, PharmD and Kara Kniska, PharmD;  
 
Cyclosporine and tacrolimus are immunosuppressive agents used for prophylaxis against graft rejection 
in transplantation, and are often used off label due to their inhibition of T cell activation in autoimmune 
disorders.
1
 With the introduction of cyclosporine in the 1970s, transplant medicine was transformed. In 
1984, tacrolimus was discovered and shown to be effective in human liver, kidney, and heart transplant 
recipients. In addition, tacrolimus did not have the adverse effects of hypertrichosis and gingival 
hyperplasia, and was associated with lower graft failure rates in kidney transplant patients when 
compared to cyclosporine.
2,3
 However, both cyclosporine and tacrolimus are limited by their 
nephrotoxicity. Cyclosporine has more data associated with its nephrotoxicity due to an extended time 
on the market. The nephrotoxic effects of tacrolimus may be slightly less, but ultimately the effects of 
both medications are thought to be due to a similar mechanism despite their structural differences .
2,3  
The rate of nephrotoxicity cited in the literature is variable (table 1), but is dependent on transplanted 
organ and years of exposure.  For instance, 7-21% of non-renal solid organ transplant recipients after 
five years of exposure to calcineurin inhibitors had chronic kidney disease (defined as a GFR 
<29ml/min/1.73M).
4
  In a study of 120 kidney-pancreas transplant recipients, after 10 years of 
calcineurin inhibition nephrotoxicity was universal on biopsy with 60% of these patients having severe 
allograft dysfunction. 
5 
While cyclosporine and tacrolimus are not structurally related, both agents work by inhibiting 
calcineurin, a calcium/calmodulin dependent phosphatase, which ultimately inhibits T-Cell activation. 
Cyclosporine binds to cyclophylin and tacrolimus binds with FKBP12. These complexes antagonize 
calcineurin preventing downstream phosphatase activity, including a decreased actuation of the nuclear 
factor of activated T- cells (NFAT). NFAT promotes transcription of IL-2 and activation of T-cells.
2,6
 Due to 
differences in molecular structure and binding characteristics, nephrotoxicity induced by cyclosporine 
and tacrolimus is thought to be related to the inhibition of calcineurin and NFAT.
2,6
  
Initial consideration of cyclosporine-induced toxicity was thought to be a reversible side effect due to 
functional changes. This was known as acute nephrotoxicity.
2
 Unfortunately in 1984, Myers and 
colleagues suggested in heart transplant patients that long term use was associated with permanent and 
progressive tubule interstitial injury and glomerulosclerosis.
7
 The probable pathophysiology of acute and 
chronic injury due to calcineurin inhibitors (CNIs) will be reviewed (figure 1). 
Acute CNI Nephrotoxicity: 
Acute calcineurin inhibitor induced nephrotoxicity is primarily due to acute arteriolopathy. The original 
finding of acute arteriole vasoconstriction caused by cyclosporine on the afferent arterioles was first 
discovered by Murray and colleagues and later confirmed by subsequent studies.
2
 Additional research 
has shown a change in vascular flow and a decreased diameter of the afferent arteriole with 
cyclosporine treatment.
8,9
 Afferent arteriole vasoconstriction has been seen with tacrolimus but has a 
lower potential of acute arteriolar constriction compared with cyclosporine. This finding has been 
consistent in both animal and human studies .
2,10
 Even though tacrolimus has been found to have less 
arteriole vasoconstriction, it is still clinically significant and presents a significant challenge when 
managing patients.   
2 
 
The true etiology of acute arterial effects has yet to be clearly established. It is thought to be 
multifactorial, resulting from a combination of an increase in vasoconstrictive factors (endothelin and 
thromboxane), activation of the renin- angiotensin- aldosterone system (RAAS), reduction of vasodilator 
factors (nitric oxide (NO) and prostacycline), and formation of free radicals.
 2,8,11
 Endothelin is released 
from cultured renal epithelial cells when exposed to cyclosporine. This finding has been confirmed in 
both animal and human studies with tacrolimus and cyclosporine.  Additional endothelial dysfunction 
occurs via the inhibition of NO synthesis resulting in a decreased production of vasodilators.
2
 Endothelial 
dysfunction promotes platelet aggregation and prothrombotic activity in the glomeruli. Activation of 
RAAS system with CNIs involves both direct and indirect mechanisms. Directly, CNIs can activate 
juxtaglomerular cells to release renin. Indirectly, CNIs can cause renin release from decreased perfusion 
as a result of arteriolar vasoconstriction.
2,11,12
 Ultimately, increased renin production increases 
angiotensin II resulting in vasoconstriction. Additionally, decreased levels of cyclooxygenase (COX-2) 
have been found with CNI administration. This is due to an association with NFAT, which has important 
implications on the gene transcription of COX-2. By inhibiting calcinurein/NFAT, the production of COX- 
2 is attenuated which would contribute to afferent arteriole vasoconstriction.
2
  In addition to this 
arteriolar imbalance tacrolimus has been shown to activate the thiazide channel causing hypertension 
which directly contributes to long-term kidney damage
13
.  
Chronic CNI Nephrotoxicity: 
Even though CNIs have significantly contributed to the advancement in transplantation, the 
disadvantage associated with CNIs is the chronic nephrotoxicity. This includes irreversible deterioration 
of renal function as a result of interstitial fibrosis, tubular atrophy, arteriolar hyalinosis, as well as 
glomerulosclerosis.
14,15
 Part of the mechanism of chronic interstitial nephritis is thought to be influenced 
by the acute effects. These include afferent arteriole vasoconstriction, local hypoxia or ischemia, free 
radical formation, and activation of the RAAS system, in particular angiotensin II and aldosterone.
2, 11, 15
 
 Secondary release of aldosterone is thought to play a significant role in chronic CNI nephropathy. 
Aldosterone can release growth factors, release reactive oxidative species, and inhibit extracellular 
matrix degradation.
10,13
 Aldosterone inhibitors (eplerenone and spironolactone) have been studied for 
their protective effects in rodents. Rodents who received a mineralocorticoid receptor antagonist in 
addition to cyclosporine, compared to those who were just given cyclosporine, had significantly less 
associated arteriolopathy and tubulointersitial fibrosis, reduced renal tissue injury, hypofiltration, 
hypertension, and growth impairment.  The rodents also sustained creatinine clearance .
13,14,15
 Sustained 
creatinine clearance suggests that inhibiting aldosterone may protect against acute nephropathy. 
Unfortunately, this has not been studied in humans.  
Up regulation of transforming growth factor beta (TGB-F), a growth factor is also thought to have 
important implications in chronic CNI toxicity. TGB-F decreases the breakdown and encourages the 
production of extracellular matrix proteins, which ultimately promotes interstitial fibrosis. This growth 
factor has been shown to be elevated upon CNI administration. Other potential factors linked with CNI 
chronic nephropathy include macrophage infiltration, ischemia, and reactive oxidative species .
2,13
  
 
3 
 
Prevention and Treatment of Nephropathy: 
Managing the adverse effects associated with CNI toxicity can be challenging. Systemic hypertension is 
the primary adverse effect associated with renal artery constriction and activation of RAAS.  Electrolyte 
disturbances can also result from CNI induced nephrotubular dysfunction resulting in hyperkalemia, 
hypomagnesemia, hyperchloremic metabolic acidosis, and hyperuricemia.
2
  
A concentration toxicity relationship has been established with CNIs thus concentration dependent 
effects must be monitored. CNIs have a narrow therapeutic index in which high plasma concentrations 
can result in acute nephrotoxicity (leading to chronic toxicity), and low plasma levels are associated with 
graft rejection.
17
 Due to the high interpatient pharmacokinetic variability, particularly with absorption 
and metabolism, plasma concentrations should be measured to ensure the patient is optimally 
treated.
1,2,10
 Unfortunately even with therapeutic drug monitoring, local renal accumulation can occur.
2,8
  
Research has been done in transplant recipients regarding avoidance, withdrawal, and minimization of 
CNIs to prevent these toxicities. Current practice and research suggests minimization of CNIs after the 
initial transplant period to target lower plasma concentrations appears to be safe. However, there are 
no studies available to date that provide evidence supporting a reduction in CNI nephrotoxicity without 
an increased rejection occurrence.
18
  
Because vasoconstriction of the afferent arteriole plays a central role with acute nephrotoxicity, 
medications that dilate the afferent arteriole have been studied to treat the acute toxicity. Treatment 
with a calcium channel blocker (CCB), such as amlodipine or nifedipine, has shown to improve blood 
pressure control and maintain glomerular filtration.
2
 In renal transplant patients, use of a calcium 
channel blocker has additionally shown to have better renal allograft function independent of its effects 
on blood pressure after one year of therapy.
16
 In a Cochrane review of renal transplant patients, when 
compared to placebo, the use of a CCB resulted in a reduction of graft loss and improved glomerular 
filtration.
17
 In heart transplant recipients, CCBs helped improve both renal function and blood pressure. 
However, with long term treatment, CCBs did not influence the evolution of renal function.
2,16,17
 This 
study did not specify which type of calcium channel blocker, dihydropyridine vs non- dihydropyridine, 
was used. Different CCBs can affect renal vasculature and CNI metabolism differently.
18
  
The central role of RAAS activation could suggest a role for an ACE inhibitor (ACEi) or angiotensin II 
receptor blocker (ARB). In rodents, it has been demonstrated that these agents can prevent cyclosporine 
induced interstitial fibrosis and improve renal function. In humans, ACEi have decreased CNI induced 
nephrotoxicity and improved alterations in blood pressure. ARBs have shown to decrease the plasma 
levels of TGF-B and endothelin. However, creatinine clearance tends to lack improvement due to 
decrease filtration as a result of dilation of the efferent arteriole.
2,8,11
 As mentioned previously, 
spironolactone has shown in rodents to decrease aldosterone mediated effects, but no human studies 
are available.
11
  
There have been two randomized studies comparing lisinopril (an ACEi) versus nifedipine (a CCB) in renal 
transplant patients. Mourad and colleagues found no change in renal function and a similar change in 
mean arterial pressure.
20
 Midtvedt and colleagues found that both lisinopril and nifedipine were 
effective in treating hypertension.
21
 However, patients receiving nifedipine had improved kidney 
 Acute Nephrotoxicity
filtration rates and thus kidney function that was sustained over a
Review when comparing an ACEi with a CCB
hyperkalemia with an ACEi. The incidence of decreased 
beneficial effect found was decreased proteinuria
for the treatment of chronic CNI nephrotoxicity
antibodies, antioxidants, statins, and magnesium supplementation. 
data, or have not shown a beneficial effect on chronic C
Tacrolimus and cyclosporine have become a cornerstone of transplant
agents differ in terms of molecular structure and side effects. T
tremor, and hypomagnesmia, while 
hyperplasia, and higher low density 
cause acute and chronic nephrotoxicity partiall
agents necessitate therapeutic drug monitoring
agents should be utilized for the treatment of hypertension
important aim of therapy includes avoiding concurrent nephrotoxic medications
on targeting other potential mechanis
 
 
 
 
 
PLT: platelet, NO: nitric oxide, GFR: glomerular filtration rate; 
oxygen species, TGF-B: transforming growth factor beta
Tubulo- Interstitium 
Electrolyte Disturbances 
 
Figure 1: Calcineurin Inhibitor Nephrotoxicity
Chronic Nephrotoxicity
 period of 2 years.
21
 A C
 found a decreased GFR in humans and increased 
graft function was inconclusive
 with ACEi use.
19
 Alternative agents have been studied
 including: misoprostol, L- arginine, anti
These agents are lacking in human 
NI toxicity in humans.
2,8,11
  
 immunosuppression
acrolimus has more associated 
cyclosporine has the adverse effects of hirsutism, gingival 
lipoprotein (LDL) and triglyceride levels.  However, 
y elucidated by the calcineurin inhibition. Both of these 
 to help limit these toxicities. Calcium ch
 and prevention of nephrotoxicity
. Future therapies focus
tic causes of acute and chronic nephrotoxicity.  
RAAS: Renin- Angiotensin- Aldosterone System
 
Interstitial Fibrosis & Ischemia
 
Tubulo- Interstitium 
↑ROS 
↑TGF-B  
 
 
4 
ochrane 
. The only 
 
- TGF-B 
 therapy. The 
diabetes, 
both agents 
annel blocking 
. Another 
 
 
; ROS: reactive 
 
Glomerulus
↑ PLT Aggregation
↑ Prothrombotic Activity
Arterioles: 
↓Vasodilators 
 (Prostacycline & NO)
↑ Vasoconstrictors 
(Thromboxane& 
↓COX-2 
↑ RAAS 
 
5 
 
 
Organ Transplant Duration of Exposure 
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